GlassScriptPhysician profile
Alexander Gluzman
NPI 1194900704
$4,371.77
in general payments reported to CMS, 2019-2025
35 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 84% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $149 · 2021: $225 · 2022: $70.47 · 2023: $501 · 2024: $1,269 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333 · Education: $57.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,332.95 |
| Education | $57.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $904.47 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Insmed, INC. | $472.47 | 2023-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $457.29 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $272.62 | 2019-2024 | |
| Verona Pharma, INC. | $261.42 | 2025 | Ohtuvayre |
| Amgen INC. | $174.79 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $162.52 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.84 | 2019-2025 | Ofev, Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $150.26 | 2024-2025 | Cuvitru |
| Harmony Biosciences LLC | $140.64 | 2020-2025 | Wakix |
| Genzyme Corporation | $132.65 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $120.79 | 2019-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $119.86 | 2019-2023 | Opsumit |
| Grifols USA, LLC | $117.38 | 2024-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $96.43 | 2025 | Sunosi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $72.82 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $53.12 | 2023-2025 | Winrevair, Belsomra |
| Teva Pharmaceuticals USA, INC. | $49.64 | 2020-2022 | |
| Viatris Specialty LLC | $48.91 | 2025 | Yupelri |
| Mallinckrodt Enterprises LLC | $42.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $35.69 | 2019-2021 | |
| Edwards Lifesciences Corporation | $34.69 | 2024 | Hemosphere |
| Zoll Medical Corporation | $33.07 | 2020 | |
| United Therapeutics Corporation | $32.27 | 2024 | Tyvaso |
| Mylan Specialty L.P. | $32.02 | 2023 | Yupelri |
| Johnson & Johnson Health Care Systems INC. | $29.73 | 2023 | Opsumit |
| Novartis Pharmaceuticals Corporation | $27.61 | 2023 | |
| Pulmonx Corporation | $23.92 | 2019 | |
| Advanced Respiratory, INC | $22.79 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.64 | 2023 | Quviviq |
| Olympus America INC. | $16.66 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.63 | 2019 | |
| Philips North America LLC | $15.47 | 2025 | Vest Therapy Und |
| Gilead Sciences, INC. | $15.46 | 2022 | |
| Resmed Corp | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Gluzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.